Keywords: ym, bio, licenses, cancer, drug, daiichi, sankyo
YM Bio licenses cancer drug to Daiichi Sankyo
Article | 07 August 2006
Canadian oncology drugs developer YM BioSciences says that its wholly-owned subsidiary, CIMYM BioSciences, has licensed Japanese development and marketing rights ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
